Sunesis initiates trial of anticancer drug
The trial is designed to examine the safety and preliminary anti-tumor activity of SNS-032 and will enroll patients with advanced solid tumor cancers. Once a maximum-tolerated dose has
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.